Newsletter
Jul 9, 2026
•
4 min read
Ipsen lands Phase III migraine data, Tarsus adds IRX-101, and FDA pauses new CRL disclosures.
Jul 8, 2026
Vera flips to launch mode in IgA nephropathy, Kailera's oral GLP-1 clears Phase 3, and AZ crashes Merck's COPD party.
Jul 7, 2026
Vertex's biggest-ever check, Genmab's bispecific clears Europe, and CMS takes an axe to 340B.
Jul 6, 2026
Plus AZ's fourth CSPC raid, United's $300M thymus bet, and a soft-jobs tape.
Jul 2, 2026
Roche posts a phase III KRAS win, Orca clears the FDA, and Novartis lands an EU SMA nod.
Jul 1, 2026
Ipsen buys Memo, Canada clears generic Wegovy, and Boulevard rents a $1.6B China T-cell engager.
Jun 30, 2026
Sanofi clears a Pompe hurdle, Roche grabs a TED PDUFA, and Nuvectis grabs $100M while the window's open.
Jun 29, 2026
Ipsen buys Kartos, Viridian gets its TED approval, and Tavneos faces a sharper regulatory overhang.
Jun 26, 2026
Biogen takes the red pen to Apellis; Ionis hands off zilganersen
Jun 25, 2026
Trop-2 ADC goes frontline, an antisense pancreatitis first, and a $10.6B tender clock now ticking.
Jun 24, 2026
Two Big Pharmas circle a gene-therapy bankruptcy, and an oral GLP-1 posts 11.5%.
Jun 23, 2026
AbbVie buys its way into eczema. Plus Merck's TL1A Phase 3 win and Sanofi's EU MS nod.
Jun 22, 2026
MoonLake tees up Investor Day, Washington probes German pricing, and biotech tape stays oddly selective.
Jun 18, 2026
Biogen shops immunology, Kardigan banks $400M, and biotech tapes over a weak broader close.
Jun 17, 2026
Moderna faces the FDA panel, Lilly grabs more pain, and Merck writes another AI check.
Jun 16, 2026
Intellia rewrites HAE, Spyre stokes TL1A takeout math, and Neumora cuts a third of staff.
Jun 15, 2026
J&J leads on Phase 3 myeloma, Sanofi expands Tzield, and Lilly adds a CLL win as biotech stays bid.
Jun 12, 2026
Takeda bodies Sotyktu in a head-to-head, Penumbra gets its stroke green light, and Stockholm keeps the EHA data spigot open.
Jun 11, 2026
5 min read
Hot CPI and an oil-fueled risk-off dragged biotech down with the tape — even a record IPO and a Phase 3 win couldn't keep the screen green.
Jun 10, 2026
GSK reaches for the checkbook, Parabilis breaks the IPO record, and AstraZeneca gatecrashes the GLP-1 party.
Jun 9, 2026
Incyte spends $2B dodging its own patent cliff, J&J buys into degraders sight-unseen, AZ's diet pill stays in the race — and biotech somehow still closes red.
Jun 8, 2026
Roche hands Nurix $700M for a BTK degrader, ADA can't stop shipping obesity data, and a chip rout drags the tape to its worst day since October.
Jun 5, 2026
3 min read
First CLDN18.2 ADC into a regulatory queue, Otsuka fights for its Voyxact read, and a new bill takes aim at the China licensing trade.
Jun 4, 2026
Biotech outpaced a softer tape as Alnylam struck a $2B AI pact, Lilly licensed Ascidian's RNA editing, and Iovance added Australia.
Jun 3, 2026
J&J's nipocalimab delivers in SLE, Travere strikes a $1B kidney licensing deal, and Novo exports oral Wegovy.
